Table 1_Integrating molecular targeting and immune modulation in triple-negative breast cancer: from mechanistic insights to therapeutic innovation.xlsx
<p>Triple-negative breast cancer (TNBC) remains a clinically aggressive subtype of breast cancer, defined by the absence of estrogen receptor, progesterone receptor, and HER2 amplification, and disproportionately affecting younger and racially diverse populations. Despite conventional chemothe...
Shranjeno v:
| Glavni avtor: | |
|---|---|
| Drugi avtorji: | , , , |
| Izdano: |
2025
|
| Teme: | |
| Oznake: |
Označite
Brez oznak, prvi označite!
|
| _version_ | 1849927622662815744 |
|---|---|
| author | Yueren Fan (22687577) |
| author2 | He Wang (250350) Hongyu Zhang (155876) Tianfei Ma (22687580) Yihang Zhao (6743393) |
| author2_role | author author author author |
| author_facet | Yueren Fan (22687577) He Wang (250350) Hongyu Zhang (155876) Tianfei Ma (22687580) Yihang Zhao (6743393) |
| author_role | author |
| dc.creator.none.fl_str_mv | Yueren Fan (22687577) He Wang (250350) Hongyu Zhang (155876) Tianfei Ma (22687580) Yihang Zhao (6743393) |
| dc.date.none.fl_str_mv | 2025-11-26T06:34:11Z |
| dc.identifier.none.fl_str_mv | 10.3389/fimmu.2025.1711415.s001 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/dataset/Table_1_Integrating_molecular_targeting_and_immune_modulation_in_triple-negative_breast_cancer_from_mechanistic_insights_to_therapeutic_innovation_xlsx/30718838 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Genetic Immunology triple-negative breast cancer tumor-infiltrating lymphocytes antibody-drug conjugates immunotherapy antitumor immunity |
| dc.title.none.fl_str_mv | Table 1_Integrating molecular targeting and immune modulation in triple-negative breast cancer: from mechanistic insights to therapeutic innovation.xlsx |
| dc.type.none.fl_str_mv | Dataset info:eu-repo/semantics/publishedVersion dataset |
| description | <p>Triple-negative breast cancer (TNBC) remains a clinically aggressive subtype of breast cancer, defined by the absence of estrogen receptor, progesterone receptor, and HER2 amplification, and disproportionately affecting younger and racially diverse populations. Despite conventional chemotherapy, TNBC patients often face poor prognoses due to the lack of actionable molecular targets and early metastatic potential. Advances in molecular profiling have unveiled distinct TNBC subtypes and actionable vulnerabilities, including BRCA1/2 mutations and PI3K/AKT/mTOR dysregulation. Therapies targeting DNA repair pathways, angiogenesis, and androgen receptor signaling—particularly via PARP inhibitors and antibody–drug conjugates like sacituzumab govitecan—have demonstrated clinical benefit. Concurrently, TNBC’s immunogenic nature, reflected in dense tumor-infiltrating lymphocytes (TILs), has driven the integration of immune checkpoint inhibitors. However, both primary and acquired resistance remain major barriers. This review delineates recent developments in targeted and immunotherapeutic strategies, emphasizing the role of TILs in shaping treatment response and highlighting combinatorial approaches that synergize molecular targeting with immunomodulation. Through a comprehensive understanding of TNBC’s molecular and immune landscape, we propose new therapeutic trajectories to improve clinical outcomes in this challenging malignancy.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_eb21065f26715ab987da021d3b315a4e |
| identifier_str_mv | 10.3389/fimmu.2025.1711415.s001 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/30718838 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Table 1_Integrating molecular targeting and immune modulation in triple-negative breast cancer: from mechanistic insights to therapeutic innovation.xlsxYueren Fan (22687577)He Wang (250350)Hongyu Zhang (155876)Tianfei Ma (22687580)Yihang Zhao (6743393)Genetic Immunologytriple-negative breast cancertumor-infiltrating lymphocytesantibody-drug conjugatesimmunotherapyantitumor immunity<p>Triple-negative breast cancer (TNBC) remains a clinically aggressive subtype of breast cancer, defined by the absence of estrogen receptor, progesterone receptor, and HER2 amplification, and disproportionately affecting younger and racially diverse populations. Despite conventional chemotherapy, TNBC patients often face poor prognoses due to the lack of actionable molecular targets and early metastatic potential. Advances in molecular profiling have unveiled distinct TNBC subtypes and actionable vulnerabilities, including BRCA1/2 mutations and PI3K/AKT/mTOR dysregulation. Therapies targeting DNA repair pathways, angiogenesis, and androgen receptor signaling—particularly via PARP inhibitors and antibody–drug conjugates like sacituzumab govitecan—have demonstrated clinical benefit. Concurrently, TNBC’s immunogenic nature, reflected in dense tumor-infiltrating lymphocytes (TILs), has driven the integration of immune checkpoint inhibitors. However, both primary and acquired resistance remain major barriers. This review delineates recent developments in targeted and immunotherapeutic strategies, emphasizing the role of TILs in shaping treatment response and highlighting combinatorial approaches that synergize molecular targeting with immunomodulation. Through a comprehensive understanding of TNBC’s molecular and immune landscape, we propose new therapeutic trajectories to improve clinical outcomes in this challenging malignancy.</p>2025-11-26T06:34:11ZDatasetinfo:eu-repo/semantics/publishedVersiondataset10.3389/fimmu.2025.1711415.s001https://figshare.com/articles/dataset/Table_1_Integrating_molecular_targeting_and_immune_modulation_in_triple-negative_breast_cancer_from_mechanistic_insights_to_therapeutic_innovation_xlsx/30718838CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/307188382025-11-26T06:34:11Z |
| spellingShingle | Table 1_Integrating molecular targeting and immune modulation in triple-negative breast cancer: from mechanistic insights to therapeutic innovation.xlsx Yueren Fan (22687577) Genetic Immunology triple-negative breast cancer tumor-infiltrating lymphocytes antibody-drug conjugates immunotherapy antitumor immunity |
| status_str | publishedVersion |
| title | Table 1_Integrating molecular targeting and immune modulation in triple-negative breast cancer: from mechanistic insights to therapeutic innovation.xlsx |
| title_full | Table 1_Integrating molecular targeting and immune modulation in triple-negative breast cancer: from mechanistic insights to therapeutic innovation.xlsx |
| title_fullStr | Table 1_Integrating molecular targeting and immune modulation in triple-negative breast cancer: from mechanistic insights to therapeutic innovation.xlsx |
| title_full_unstemmed | Table 1_Integrating molecular targeting and immune modulation in triple-negative breast cancer: from mechanistic insights to therapeutic innovation.xlsx |
| title_short | Table 1_Integrating molecular targeting and immune modulation in triple-negative breast cancer: from mechanistic insights to therapeutic innovation.xlsx |
| title_sort | Table 1_Integrating molecular targeting and immune modulation in triple-negative breast cancer: from mechanistic insights to therapeutic innovation.xlsx |
| topic | Genetic Immunology triple-negative breast cancer tumor-infiltrating lymphocytes antibody-drug conjugates immunotherapy antitumor immunity |